Neridronic acid
Neridronic acid
 |
| Systematic (IUPAC) name |
|---|
|
(6-Amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid) |
| Clinical data |
|---|
| Identifiers |
|---|
|
79778-41-9  Y |
|---|
|
None |
|---|
| PubChem |
CID 71237 |
|---|
| ChemSpider |
64372  N |
|---|
| UNII |
8U27U3RIN4 N |
|---|
| Chemical data |
|---|
| Formula |
C6H17NO7P2 |
|---|
|
277.14 g/mol |
|---|
SMILES
- C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
|
InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
N
Key:PUUSSSIBPPTKTP-UHFFFAOYSA-N
N
|
| N (what is this?) (verify) |
|---|
Neridronic acid (INN; the anion is called neridronate) is a bisphosphonate. In Italy it is used to treat Osteogenesis imperfecta and Paget's disease of bone.[1]
A 2013 clinical trial suggests CRPS Type I (Complex regional pain syndrome) responds to treatment with intravenous neridronate.[2]
References
- ↑ NIH
- ↑ Varenna M, Adami S, Rossini M et al. (March 2013). "Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study". Rheumatology 52 (3): 534–42. doi:10.1093/rheumatology/kes312. PMID 23204550.
|
|---|
| | Bisphosphonates | |
|---|
| | Bone morphogenetic proteins | |
|---|
| | Other | |
|---|
| |
|---|
| | Description |
- Anatomy
- bones
- skull
- face
- neurocranium
- compound structures
- foramina
- upper extremity
- torso
- pelvis
- lower extremity
- Physiology
- Development
- Cells
|
|---|
| | Disease |
- Congenital
- Neoplasms and cancer
- Trauma
- Other
- Symptoms and signs
|
|---|
| | Treatment | |
|---|
|
|